NEWS

BIOSC, KEDRION’S EXCELLENCE IN THE NEW BIOLOGICAL SAFETY CENTRE FOR VIRAL VALIDATION STUDIES
27/07/2010

KEDRION SPA. BOARD OF DIRECTORS APPROVES 2009 FINANCIAL STATEMENTS
07/05/2010

KEDRION RECEIVES QSEAL CERTIFICATION FROM PPTA
08/02/2010

GROWTH OF THE KEDRION GROUP: EXPANSION OF THE HUNGARIAN PLANT STARTING NOW. A NEW PLASMAPHERESIS CENTRE SETTLED IN BUDAPEST
02/12/2009

HAEMOPHILIA: KEDRION WINS AWARD IN INDIA
09/01/2009

KEDRION: AIFA’S INCENTIVES TO SEVEN INVESTMENT PLANS
09/01/2009

KEDRION GROUP: INVESTMENTS AND ACQUISITIONS TO EXPAND ITS MARKET SHARE
13/11/2008

INCREASED PRODUCT RANGE: STUDIES ON FIBRIN GLUE JUST STARTED
03/11/2008

NEW METHOD FOR THE PURIFICATION OF FACTOR VIII VIII/FvW CONCENTRATE STUDY PUBLISHED ON
30/10/2008

VIRAL RISK ASSESSMENT: KEDRION WINS THE SIMTI AWARD
27/10/2008

FOUR NEW DEPARTMENTS IN THE BOLOGNANA SITE. INVESTMENTS IN CONTINUOUS PLANT AND PROCESS IMPROVEMENT KEEP FLOWING
26/05/2008

AGREEMENT BETWEEN KEDRION AND PROMETIC FOR THE DEVELOPMENT OF HYPERIMMUNE PRODUCTS
13/03/2008

VISIT OF THE MINISTER OF REFORM AND INNOVATION IN THE PUBLIC ADMINISTRATION, LUIGI NICOLAIS, TO THE KEDRION PLANT IN SANT’ANTIMO (NAPLES)
12/03/2008

PAOLO MARCUCCI HAS JOINED PPTA’S GLOBAL BOARD OF DIRECTORS
28/02/2008

EUROPEAN GMP, CURRENT ISSUES AND FUTURE DEVELOPMENTS: KEDRION IN THE ORGANISING COMMITTEE OF THE EMEA / PDA JOINT CONFERENCE
19/02/2008

PRODUCTION OF PLASMA-DERIVED PRODUCTS TO HIGHEST INTERNATIONAL QUALITY STANDARDS: KEDRION TECHNOLOGY FOR THE NEW MOSCOW PLANT
01/02/2008

KEDRION BUYS A PRODUCTION PLANT IN HUNGARY FROM TEVA PHARMACEUTICAL INDUSTRIES LTD
21/12/2007

KEDRION STAKES ON “VERTICAL INTEGRATION”. TWO AGREEMENTS SIGNED TO BUY FOUR PLASMA COLLECTION CENTRES IN THE USA AND GERMANY
26/11/2007

NEW METHOD FOR PURIFYING PLASMA PROTEINS USED TO TREAT HAEMOPHILIA A AND VON WILLEBRAND DISEASE
31/10/2007

HUMAN PLASMINOGEN ACKNOWLEDGED AS ORPHAN DRUG
15/10/2007

EMAS REGISTRATION FOR KEDRION: THE COMPANY’S ENVIRONMENTAL POLICY REINFORCED.
14/09/2007

RESEARCH PROJECT FOR DEVELOPING A NEW PLASMA DERIVATIVE FOR THE TREATMENT OF HEPATITIS C
20/07/2007

NEW PLANT IN THE KEDRION FACTORY: 7 MILLION INVESTED AND A 50% INCREASE IN PRODUCTION OF FACTOR VIII AND FACTOR IX
15/05/2007

KEDRION AND PROMETIC FORM STRATEGIC ALLIANCE TO DEVELOP ORPHAN DRUGS FROM PLASMA
20/03/2007

KEDRION AND NABI BIOPHARMACEUTICALS ANNOUNCE INITIATION OF CIVACIR® PHASE II 'PROOF-OF-CONCEPT' CLINICAL TRIAL
07/02/2007

PLASMADERIVATIVES: “INVESTITORI ASSOCIATI” INVESTS IN THE SECTOR WITH A 40% SHARE IN LEADING COMPANY KEDRION
18/12/2006

NABI BIOPHARMACEUTICALS SECURES AGREEMENT WITH KEDRION TO CO-DEVELOP AND COMMERCIALIZE CIVACIR® IN EUROPE
07/07/2006

PLASMA SYSTEM, EXPORTING THE ITALIAN “CONTRACT MANUFACTURING” MODEL TO CHILE
12/06/2006

PLASMA DERIVATES: REINFORCING TUSCANY AS LEADER IN THE BALKANS
29/05/2006

VON WILLEBRAND DISEASE”: SIMPLE HANDBOOK
10/05/2006

HAEMOPHILIA: TREATMENT AND CARE “UNDER ANALYSIS”
08/05/2006

FIRST RUSSIAN FACTORY PRODUCING PLASMA-DERIVED PRODUCTS OF INTERNATIONAL STANDARD TO BE SET UP WITH KEDRION TECHNOLOGY
14/02/2006

Working Party on Desmopressin in the management of VWD
16/09/2005